ArticleJournal of diabetes science and technology2021
Performance of the Prototype NovioSense Noninvasive Biosensor for Tear Glucose in Type 1 Diabetes.
Article in Journal of diabetes science and technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Review
- Tear glucose is associated with the presence and severity of diabetic retinopathy.International journal of retina and vitreous · 2025Article
- AI-Based Noninvasive Blood Glucose Monitoring: Scoping Review.Journal of medical Internet research · 2024Article
- In-depth correlation analysis between tear glucose and blood glucose using a wireless smart contact lens.Nature communications · 2024Article
- Changes in tear glucose and insulin concentrations following an oral glucose tolerance test.Clinical & experimental optometry · 2023Article
- Noninvasive Glucose Sensing In Vivo.Sensors (Basel, Switzerland) · 2023Review
- Experimental and probabilistic model validation of ultrasonic MEMS transceiver for blood glucose sensing.Scientific reports · 2022Article
- Emerging Applications of Electrochemical Impedance Spectroscopy in Tear Film Analysis.Biosensors · 2022Review
- Quantification of tear glucose levels and their correlation with blood glucose levels in dogs.Veterinary medicine and science · 2022Article
- Commercial and Scientific Solutions for Blood Glucose Monitoring-A Review.Sensors (Basel, Switzerland) · 2022Review
- Sense and Learn: Recent Advances in Wearable Sensing and Machine Learning for Blood Glucose Monitoring and Trend-Detection.Frontiers in bioengineering and biotechnology · 2022Review
- Products for Monitoring Glucose Levels in the Human Body With Noninvasive Optical, Noninvasive Fluid Sampling, or Minimally Invasive Technologies.Journal of diabetes science and technology · 2022Review
- Exhaled Breath Analysis for Diabetes Diagnosis and Monitoring: Relevance, Challenges and Possibilities.Biosensors · 2021Review
- Small-volume detection: platform developments for clinically-relevant applications.Journal of nanobiotechnology · 2021Review
- Continuous monitoring of diabetes with an integrated microneedle biosensing device through 3D printing.Microsystems & nanoengineering · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe recently published the results of a pilot study measuring glucose in tear fluid. We now show the results of an additional 24 patients.
methodsTwenty-four subjects were recruited from Haaglanden Diabetes Centre. The patients reported in a fasting state and were given a meal with half the usual dose of insulin during the test. The device was applied under the lower eyelid. Glucose levels from capillary blood and interstitial fluid with a flash glucose measurement device were recorded every 15 minutes; the current from the tear glucose sensor was recorded continuously. The eye surface and tolerability were regularly checked. A calibration algorithm to convert tear glucose to blood values was built using a neural network regression model and validated.
resultsNo adverse events were attributed to the sensor coil placed under the lower eyelid. The mean absolute relative difference for the 24-patient subset was 16.7 (after 6 hours total time in the eye). The median absolute relative difference was 13.3. Compared to published data from Abbott (15.7 on day 1), the present device is comparable to Libre, considering that the device was allowed only one hour of equilibration time before the measurements were made.
conclusionThe NovioSense Tear glucose sensor measures blood glucose values with an acceptable accuracy and may become a good alternative to invasive devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.